$651 Million is the total value of Octagon Capital Advisors LP's 40 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 46.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $119,065,200 | -50.1% | 3,130,000 | +19.5% | 18.29% | -44.9% |
| Buy | ROIVANT SCIENCES LTD | $51,006,560 | +29.6% | 4,367,000 | +11.9% | 7.84% | +43.1% | |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $45,829,613 | -8.4% | 3,073,750 | -32.8% | 7.04% | +1.1% |
| VRNA | Sell | VERONA PHARMA PLCsponsored ads | $38,614,700 | -26.0% | 2,369,000 | -4.0% | 5.93% | -18.3% |
| IMVT | New | IMMUNOVANT INCput | $38,390,000 | – | 1,000,000 | +100.0% | 5.90% | – |
| RCUS | ARCUS BIOSCIENCES INC | $35,325,600 | -11.6% | 1,968,000 | 0.0% | 5.43% | -2.4% | |
| INSM | Buy | INSMED INC | $32,421,000 | +318.7% | 1,284,000 | +249.9% | 4.98% | +362.1% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $28,534,022 | +5.3% | 655,051 | -12.7% | 4.38% | +16.3% |
| APLS | New | APELLIS PHARMACEUTICALS INCput | $25,677,000 | – | 675,000 | +100.0% | 3.94% | – |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $25,622,120 | +22.2% | 971,639 | -20.3% | 3.94% | +34.9% |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $20,912,393 | -18.9% | 759,898 | 0.0% | 3.21% | -10.5% | |
| ETNB | Buy | 89BIO INC | $18,823,784 | -6.9% | 1,219,157 | +14.3% | 2.89% | +2.8% |
| RPHM | Sell | RENEO PHARMACEUTICALS INC | $17,361,210 | +11.7% | 2,279,870 | -3.7% | 2.67% | +23.4% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $16,369,974 | -25.4% | 1,067,143 | +15.6% | 2.52% | -17.7% |
| APLS | New | APELLIS PHARMACEUTICALS INCcall | $15,216,000 | – | 400,000 | +100.0% | 2.34% | – |
| Buy | AN2 THERAPEUTICS INC | $13,950,606 | +127.7% | 867,575 | +20.3% | 2.14% | +151.2% | |
| New | AMYLYX PHARMACEUTICALS INC | $12,725,450 | – | 695,000 | +100.0% | 1.96% | – | |
| TSHA | New | TAYSHA GENE THERAPIES INC | $8,777,778 | – | 2,777,778 | +100.0% | 1.35% | – |
| ALPN | ALPINE IMMUNE SCIENCES INC | $8,587,500 | +11.4% | 750,000 | 0.0% | 1.32% | +22.9% | |
| GOSS | Buy | GOSSAMER BIO INC | $6,818,869 | +43.6% | 8,187,883 | +106.9% | 1.05% | +58.5% |
| AVTE | Sell | AEROVATE THERAPEUTICS INC | $6,749,311 | -36.7% | 497,370 | -20.0% | 1.04% | -30.1% |
| New | DIANTHUS THERAPEUTICS INC | $6,561,600 | – | 480,000 | +100.0% | 1.01% | – | |
| DYN | DYNE THERAPEUTICS INC | $6,208,787 | -20.4% | 692,945 | 0.0% | 0.95% | -12.1% | |
| PMVP | Buy | PMV PHARMACEUTICALS INC | $5,550,560 | +88.7% | 904,000 | +92.3% | 0.85% | +108.6% |
| INZY | Buy | INOZYME PHARMA INC | $5,460,000 | +1872.3% | 1,300,000 | +2515.6% | 0.84% | +2051.3% |
| Sell | XILIO THERAPEUTICS INC | $4,892,035 | -23.0% | 2,318,500 | -4.4% | 0.75% | -14.9% | |
| ANNX | Buy | ANNEXON INC | $4,838,000 | -17.2% | 2,050,000 | +23.5% | 0.74% | -8.6% |
| GLYC | GLYCOMIMETICS INC | $4,500,000 | -13.8% | 3,000,000 | 0.0% | 0.69% | -4.8% | |
| VKTX | VIKING THERAPEUTICS INC | $4,151,250 | -31.7% | 375,000 | 0.0% | 0.64% | -24.6% | |
| GLUE | Buy | MONTE ROSA THERAPEUTICS INC | $3,893,767 | +2756.4% | 812,895 | +3984.9% | 0.60% | +3047.4% |
| JASPER THERAPEUTICS INC | $3,127,680 | -48.9% | 4,468,114 | 0.0% | 0.48% | -43.5% | ||
| CNTA | Buy | CENTESSA PHARMACEUTICALS PLCsponsored ads | $3,077,132 | +20.7% | 475,600 | +15.5% | 0.47% | +33.2% |
| VIR | Sell | VIR BIOTECHNOLOGY INC | $3,045,719 | -80.9% | 325,050 | -50.0% | 0.47% | -78.9% |
| TVTX | New | TRAVERE THERAPEUTICS INCcall | $2,682,000 | – | 300,000 | +100.0% | 0.41% | – |
| LXRX | LEXICON PHARMACEUTICALS INC | $2,096,153 | -52.4% | 1,923,076 | 0.0% | 0.32% | -47.5% | |
| ORIC | Sell | ORIC PHARMACEUTICALS INC | $1,237,225 | -42.4% | 204,500 | -26.2% | 0.19% | -36.5% |
| ITOS | Sell | ITEOS THERAPEUTICS INC | $1,116,900 | -85.8% | 102,000 | -82.9% | 0.17% | -84.3% |
| CBAY | New | CYMABAY THERAPEUTICS INCput | $894,600 | – | 60,000 | +100.0% | 0.14% | – |
| New | BIONOMICS LIMITEDads | $453,600 | – | 168,000 | +100.0% | 0.07% | – | |
| Sell | HEPION PHARMACEUTICALS INC | $336,825 | -79.3% | 67,500 | -56.5% | 0.05% | -77.0% | |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -550,000 | -100.0% | -0.06% | – |
| PIRS | Exit | PIERIS PHARMACEUTICALS INC | $0 | – | -6,600,000 | -100.0% | -0.15% | – |
| VERA | Exit | VERA THERAPEUTICS INCcl a | $0 | – | -70,000 | -100.0% | -0.16% | – |
| ISEE | Exit | IVERIC BIO INCput | $0 | – | -50,000 | -100.0% | -0.27% | – |
| STOK | Exit | STOKE THERAPEUTICS INC | $0 | – | -185,669 | -100.0% | -0.28% | – |
| Exit | STRUCTURE THERAPEUTICS INCsponsored ads | $0 | – | -75,000 | -100.0% | -0.43% | – | |
| GERN | Exit | GERON CORP | $0 | – | -2,278,000 | -100.0% | -1.02% | – |
| TVTX | Exit | TRAVERE THERAPEUTICS INC | $0 | – | -495,000 | -100.0% | -1.06% | – |
| TNDM | Exit | TANDEM DIABETES CARE INC | $0 | – | -474,929 | -100.0% | -1.62% | – |
| Exit | DISC MEDICINE INC | $0 | – | -415,000 | -100.0% | -2.56% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.